Skip to main content

Table 1 Patient characteristics

From: Characterization of immune cells in psoriatic adipose tissue

(n = 30) Median (IQR)
Age (years) 54 (41–61)
Male, count (%) 35 (54)
Psoriasis Disease Duration (years) 20 (9–32)
Body Surface Area Score [Mean (SD)] 9.2 (16)
PASI Score [Mean (SD)] 7.8 (9.3)
Psoriatic Arthritis, count (%) 25 (38)
DMARD Therapy, count (%) 6 (9)
Biologic Therapy, count (%) 25 (39)
NSAID Therapy, count (%) 15 (23)
Phototherapy, count (%) 3 (5)
Topical Steroid Therapy, count (%) 24 (37)
Systemic Steroid Therapy, count (%) 1 (2)
Diabetes Mellitus, count (%) 7 (11)
Hypertension, count (%) 21 (32)
Dyslipidemia, count (%) 44 (68)
Current Tobacco Use, count (%) 6 (9)
Former Tobacco Use, count (%) 18 (28)
Diabetes Mellitus Therapy, count (%) 4 (6)
Anti-Hypertensive Therapy, count (%) 12 (19)
Dyslipidemia therapy, count (%) 24 (37)
Body Mass Index (kg/m2) 29 (25.9-32.3)
Systolic Blood Pressure (mm Hg) 125 (116–135)
Diastolic Blood Pressure (mm Hg) 72 (65–78)
Fasting Blood Glucose (mg/dL) 94 (89–104)
Total Cholesterol (mg/dL) 184 (158–203)
Triglycerides (mg/dL) 108 (84–137)
High-Density Lipoprotein Cholesterol (mg/dL) 52 (42–63)
Low-Density Lipoprotein Cholesterol (mg/dL) 96 (80–125)
Erythrocyte Sedimentation Rate (mm/hr) 8 (5–13)
High-Sensitivity C-Reactive Protein (g/dL) 1.7 (0.7-4.2)
  1. IQR = Interquartile Range, PASI = Psoriasis Area and Severity Index, DMARD = Disease-Modifying Anti-Rheumatic Drug, NSAID = Non-Steroidal Anti-Inflammatory Drug. Data are reported as median (IQR) unless indicated otherwise.
  2. DMARD therapy denotes methotrexate use, except for 1 patient who was taking both methotrexate and hydroxychloroquine. Biologic therapy indicates active TNF antagonist or anti-IL-12/23 receptor use except for one patient who was treated with abatacept for psoriatic arthritis.